Email this article GLUCOCORTICOIDS IN THE THERAPY OF SYSTEMIC LUPUS ERYTHEMATOSUS
- Authors: Reshetnyak T.M.1, Seredavkina N.V.1, Dydykina I.S.1, Nasonov E.I.1
-
Affiliations:
- V.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences
- Issue: Vol 7, No 3-4 (2013)
- Pages: 14-26
- Section: REVIEW
- Published: 14.07.2014
- URL: https://klinitsist.abvpress.ru/Klin/article/view/6
- DOI: https://doi.org/10.17650/1818-8338-2013-3-4-14-26
- ID: 6
Cite item
Full Text
Abstract
Despite a more than fifty-year period after the introduction of glucocorticoids (GCs) into therapeutic practice; they have headed the list of anti-inflammatory drugs so far. The paper analyzes current views on the terminology of GCs, mechanism of action, standardization of indications for their use in systemic lupus erythematosus, choice of a dose and a regimes of the drugs, as well as the rates of their decrease; the authors also review Russian and foreign literature on this problem and their own data.
Keywords
About the authors
T. M. Reshetnyak
V.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences
Author for correspondence.
Email: t_reshetnyak@yahoo.com
Russian Federation
N. V. Seredavkina
V.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical SciencesRussian Federation
I. S. Dydykina
V.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical SciencesRussian Federation
E. I. Nasonov
V.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical SciencesRussian Federation
References
Supplementary files
